Skip to main content
×
Home
    • Aa
    • Aa

Chemical and pharmacological chaperones as new therapeutic agents

  • Tip W. Loo (a1) and David M. Clarke (a1)
Abstract

Proteins that are exported from the cell, or targeted to the cell surface or other organelles, are synthesised and assembled in the endoplasmic reticulum and then delivered to their destinations. Point mutations – the most common cause of human genetic diseases – can inhibit folding and assembly of the protein in the endoplasmic reticulum. The unstable or partially folded mutant protein does not undergo trafficking and is usually rapidly degraded. A potential therapy for protein misfolding is to correct defective protein folding and trafficking using pharmacological chaperones. Pharmacological chaperones are substrates or modulators that appear to function by directly binding to the partially folded biosynthetic intermediate to stabilise the protein and allow it to complete the folding process to yield a functional protein. Initial clinical studies with pharmacological chaperones have successfully reduced clinical symptoms of disease. Therefore, pharmacological chaperones show great promise as a new class of therapeutic agents that can be specifically tailored for a particular genetic disease.

Copyright
Corresponding author
*Corresponding author: David M. Clarke, Department of Medicine, University of Toronto, Rm 7342, Medical Sciences Building, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada. Tel/Fax: +1 416 978 1105; E-mail: david.clarke@utoronto.ca
References
Hide All
1Sanders C.R. and Myers J.K. (2004) Disease-related misassembly of membrane proteins. Annu Rev Biophys Biomol Struct 33, 25-51
2Stenson P.D. et al. (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21, 577-581
3Ng P.C. and Henikoff S. (2006) Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7, 61-80
4Hebert D.N., Garman S.C. and Molinari M. (2005) The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol 15, 364-370
5Kopito R.R. (1997) ER quality control: the cytoplasmic connection. Cell 88, 427-430
6Pedrola L. et al. (2005) GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 14, 1087-1094
7Sekijima Y. et al. (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85
8Schroder M. and Kaufman R.J. (2005) The mammalian unfolded protein response. Annu Rev Biochem 74, 739-789
9Pearse B.R. and Hebert D.N. (2006) Cotranslocational degradation: utilitarianism in the ER stress response. Mol Cell 23, 773-775
10Horwich A. (2002) Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions. J Clin Invest 110, 1221-1232
11Stefani M. (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739, 5-25
12Soto C., Estrada L. and Castilla J. (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31, 150-155
13Rochet J-C. (2007) Novel therapeutic strategies for treatment of protein misfolding. Expert Rev Mol Med 9, 1-34
14Aridor M. and Hannan L.A. (2002) Traffic jams II: an update of diseases of intracellular transport. Traffic 3, 781-790
15Aridor M. and Balch W.E. (1999) Integration of endoplasmic reticulum signaling in health and disease. Nat Med 5, 745-751
16De Jaco A. et al. (2006) A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family. J Biol Chem 281, 9667-9676
17Seibert F.S. et al. (1997) Cystic fibrosis: channel, catalytic, and folding properties of the CFTR protein. J Bioenerg Biomembr 29, 429-442
18Petaja-Repo U.E. et al. (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor. J Biol Chem 275, 13727-13736
19Paulson H.L. et al. (1991) Analysis of early events in acetylcholine receptor assembly. J Cell Biol 113, 1371-1384
20Quilty J.A., Li J. and Reithmeier R.A. (2002) Impaired trafficking of distal renal tubular acidosis mutants of the human kidney anion exchanger kAE1. Am J Physiol Renal Physiol 282, F810-820
21Valentijn J.A., Fyfe G.K. and Canessa C.M. (1998) Biosynthesis and processing of epithelial sodium channels in Xenopus oocytes. J Biol Chem 273, 30344-30351
22Loo T.W., Bartlett M.C. and Clarke D.M. (2002) Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments. J Biol Chem 277, 27585-27588
23Chen E.Y. et al. (2004) The ΔF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 279, 39620-39627
24Arakawa T. et al. (2006) Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764, 1677-1687
25Papp E. and Csermely P. (2006) Chemical chaperones: mechanisms of action and potential use. Handb Exp Pharmacol 405–416
26Gekko K. and Timasheff S.N. (1981) Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry 20, 4667-4676
27Sampedro J.G. and Uribe S. (2004) Trehalose-enzyme interactions result in structure stabilization and activity inhibition. Mol Cell Biochem 256–257, 319-327
28Sato S. et al. (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271, 635-638
29Burrows J.A., Willis L.K. and Perlmutter D.H. (2000) Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci U S A 97, 1796-1801
30Tamarappoo B.K. and Verkman A.S. (1998) Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 101, 2257-2267
31Tan C.M., Nickols H.H. and Limbird L.E. (2003) Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation. J Biol Chem 278, 35678-35686
32Song J.L. and Chuang D.T. (2001) Natural osmolyte trimethylamine N-oxide corrects assembly defects of mutant branched-chain alpha-ketoacid decarboxylase in maple syrup urine disease. J Biol Chem 276, 40241-40246
33Fischer H. et al. (2001) Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 281, L52-57
34Brusilow S.W. and Maestri N.E. (1996) Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr 43, 127-170
35Rubenstein R.C., Egan M.E. and Zeitlin P.L. (1997) In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100, 2457-2465
36Collins A.F. et al. (1995) Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85, 43-49
37Kubota K. et al. (2006) Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 97, 1259-1268
38Ozcan U. et al. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140
39Loo T.W. and Clarke D.M. (1997) Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators. J Biol Chem 272, 709-712
40Dean M. and Annilo T. (2005) Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 6, 123-142
41Loo T.W. and Clarke D.M. (2005) Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol 206, 173-185
42Hoof T. et al. (1994) Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J Biol Chem 269, 20575-20583
43Loo T.W. and Clarke D.M. (1998) Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate- induced transmembrane domain interactions. J Biol Chem 273, 14671-14674
44Loo T.W. and Clarke D.M. (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 274, 24759-24765
45Loo T.W., Bartlett M.C. and Clarke D.M. (2006) Insertion of an arginine residue into the transmembrane segments corrects protein misfolding. J Biol Chem 281, 29436-29440
46Rowe S.M., Miller S. and Sorscher E.J. (2005) Cystic fibrosis. N Engl J Med 352, 1992-2001
47Riordan J.R. et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073
48Cheng S.H. et al. (1990) Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834
49Yang Y. et al. (1993) The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci U S A 90, 9480-9484
50Kartner N. et al. (1992) Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1, 321-327
51Drumm M.L. et al. (1990) Correction of the cystic fibrosis defect in vitro by retrovirus- mediated gene transfer [published erratum appears in Cell 1993 Jun 16;74(1):215]. Cell 62, 1227-1233
52Denning G.M. et al. (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764
53Dalemans W. et al. (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354, 526-528
54Zhang F., Kartner N. and Lukacs G.L. (1998) Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat Struct Biol 5, 180-183
55Chen E.Y., Bartlett M.C. and Clarke D.M. (2000) Cystic fibrosis transmembrane conductance regulator has an altered structure when its maturation is inhibited. Biochemistry 39, 3797-3803
56Pedemonte N. et al. (2005) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115, 2564-2571
57Van Goor F. et al. (2006) Rescue of ΔF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290, L1117-1130
58Loo T.W., Bartlett M.C. and Clarke D.M. (2005) Rescue of ΔF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm 2, 407-413
59Loo T.W. et al. (2006) The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR processing mutants. Biochem J 395, 537-542
60Wang Y. et al. (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70, 297-302
61Wang Y. et al. (2007) Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 71, 751-758
62Egan M.E. et al. (2004) Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 304, 600-602
63Norez C. et al. (2006) Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 580, 2081-2086
64Egan M.E. et al. (2002) Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 8, 485-492
65Cormet-Boyaka E. et al. (2004) Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation. Proc Natl Acad Sci U S A 101, 8221-8226
66Johnson L.G. et al. (1992) Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 2, 21-25
67Sharma M. et al. (2001) Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem 276, 8942-8950
68Gentzsch M. et al. (2004) Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 15, 2684-2696
69Clement J.P. 4th et al. (1997) Association and stoichiometry of K(ATP) channel subunits. Neuron 18, 827-838
70Sharma N. et al. (1999) The C terminus of SUR1 is required for trafficking of KATP channels. J Biol Chem 274, 20628-20632
71Cartier E.A. et al. (2001) Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. Proc Natl Acad Sci U S A 98, 2882-2887
72Yan F. et al. (2004) Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor. J Biol Chem 279, 11096-11105
73Yan F.F., Casey J. and Shyng S.L. (2006) Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. J Biol Chem 281, 33403-33413
74Bernier V., Bichet D.G. and Bouvier M. (2004) Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol 4, 528-533
75Ulloa-Aguirre A. et al. (2006) G-protein-coupled receptor trafficking: understanding the chemical basis of health and disease. ACS Chem Biol 1, 631-638
76Morello J.P. et al. (2000) Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105, 887-895
77Janovick J.A., Maya-Nunez G. and Conn P.M. (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87, 3255-3262
78Noorwez S.M. et al. (2003) Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem 278, 14442-14450
79Petaja-Repo U.E. et al. (2002) Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. Embo J 21, 1628-1637
80Sands J.M. and Bichet D.G. (2006) Nephrogenic diabetes insipidus. Ann Intern Med 144, 186-194
81Morello J.P. and Bichet D.G. (2001) Nephrogenic diabetes insipidus. Annu Rev Physiol 63, 607-630
82Wuller S. et al. (2004) Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem 279, 47254-47263
83Futerman A.H. and van Meer G. (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5, 554-565
84Sawkar A.R., D'Haeze W. and Kelly J.W. (2006) Therapeutic strategies to ameliorate lysosomal storage disorders–a focus on Gaucher disease. Cell Mol Life Sci 63, 1179-1192
85Ishii S. et al. (1993) Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 197, 1585-1589
86Okumiya T. et al. (1995) Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun 214, 1219-1224
87Kase R. et al. (2000) Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochim Biophys Acta 1501, 227-235
88Fan J.Q. et al. (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5, 112-115
89Asano N. et al. (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 267, 4179-4186
90Yam G.H., Zuber C. and Roth J. (2005) A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. Faseb J 19, 12-18
91Sawkar A.R. et al. (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99, 15428-15433
92Sawkar A.R. et al. (2005) Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 12, 1235-1244
93Matsuda J. et al. (2003) Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A 100, 15912-15917
94Tropak M.B. et al. (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 279, 13478-13487
95Frustaci A. et al. (2001) Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345, 25-32
96Polgar O. et al. (2004) Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry 43, 9448-9456
97Shukla S. et al. (2003) Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell 2, 1361-1375
98Buyse F., Vandenbranden M. and Ruysschaert J.M. (2004) Mistargeted MRPdeltaF728 mutant is rescued by intracellular GSH. FEBS Lett 578, 145-151
99Loo T.W. and Clarke D.M. (1998) Nonylphenol ethoxylates, but not nonylphenol, are substrates of the human multidrug resistance P-glycoprotein. Biochem Biophys Res Commun 247, 478-480
100Partridge C.J., Beech D.J. and Sivaprasadarao A. (2001) Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism. J Biol Chem 276, 35947-35952
101Van Craenenbroeck K. et al. (2005) Folding efficiency is rate-limiting in dopamine D4 receptorbiogenesis. J Biol Chem 280, 19350-19357
102Valluru L. et al. (2005) Ligand binding is a critical requirement for plasma membrane expression of heteromeric kainate receptors. J Biol Chem 280, 6085-6093
103Fortin J.P. et al. (2006) A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor. Mol Pharmacol 69, 1146-1157
104Kuryatov A. et al. (2005) Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors. Mol Pharmacol 68, 1839-1851
105Yu Z. et al. (2007) Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for gaucher disease intervention. J Med Chem 50, 94-100
106Lieberman R.L. et al. (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3, 101-107
107Wiens G.D., O'Hare T. and Rittenberg M.B. (2001) Recovering antibody secretion using a hapten ligand as a chemical chaperone. J Biol Chem 276, 40933-40939
108Amat di San Filippo C., Pasquali M. and Longo N. (2006) Pharmacological rescue of carnitine transport in primary carnitine deficiency. Hum Mutat 27, 513-523
109Kim B.E. et al. (2002) A conditional mutation affecting localization of the Menkes disease copper ATPase. Suppression by copper supplementation. J Biol Chem 277, 44079-44084
110Zhou Z., Gong Q. and January C.T. (1999) Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J Biol Chem 274, 31123-31126
111Foster B.A. et al. (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510
112Chen J.K. et al. (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16, 2743-2748
113Halaban R. et al. (2001) Proper folding and endoplasmic reticulum to golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine. J Biol Chem 276, 11933-11938

The following papers describe in detail the mechanisms of protein misfolding and aggregation that are not discussed in this review. Other diseases involving protein misfolding and/or aggregations are also reviewed.

Sanders C.R. and Myers J.K. (2004) Disease-related misassembly of membrane proteins. Annu Rev Biophys Biomol Struct 33, 25-51
Arakawa T. et al. (2006) Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764, 1677-1687
Gregersen N. et al. (2006) Protein misfolding and human disease. Annu Rev Genomics Hum Genet 7, 103-124
Rochet J-C. (2007) Novel therapeutic strategies for treatment of protein misfolding. Expert Rev Mol Med 9, 1-34
Smith A.J. et al. Molecular cell biology of KATP channels: implications for neonatal diabetes. Expert Rev Mol Med (in press)

The Cystic Fibrosis Foundation provides general information about Cystic Fibrosis and updates on new therapeutic developments:

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 3
Total number of PDF views: 33 *
Loading metrics...

Abstract views

Total abstract views: 230 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st October 2017. This data will be updated every 24 hours.